Reversal of gene expression profile in the phenylketonuria mouse model after adeno-associated virus vector-mediated gene therapy

Hyun Jeong Oh, Hyejin Lee, Joo Won Park, Hwanseok Rhee, Soo Kyung Koo, Seong Man Kang, Inho Jo, Sung Chul Jung

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Phenylketonuria (PKU) is an autosomal recessive metabolic disorder caused by phenylalanine hydroxylase (PAH) deficiency. Accumulation of phenylalanine leads to severe mental and psychomotor retardation, and hypopigmentation of skin and hair. We have demonstrated the cognitive outcome of biochemical and phenotypic reversal by the adeno-associated virus vector-mediated gene delivery of a human PAH transgene. In this study, we identified the expression of genes related to pathologic abnormalities of the PKU-affected brain, in which the symptoms of PKU are mainly manifest, and transcriptional changes in effective gene therapy treatment using oligonucleotide array. Therapeutic effectiveness was verified by change in enzyme activity (15 ± 5.84%), phenylalanine plasma level (261 ± 108 μM), and coat color. Our data indicated that 12 genes were significantly up-regulated in PKU. Four are involved in defense and inflammatory responses of neutrophils (NE, MPO, NGP, and CRAMP), three other overexpressed genes are related to extracellular matrix organization and degradation (COL1A1, COL1A2, and MMP13); the remainder were a nociceptor in sensory neurons (MrgA1), a structural gene of P lysozyme (Lzp-s), an immunoglobulin α heavy chain constant region gene (Igh-2), an osteocalcin-related protein precursor (Bglap-rs1), and a membrane-spanning 4 domain, subfamily A, member 3 (Ms4a3). Data demonstrated that elevated genes in the PKU-affected brain could be normalized by human PAH gene delivery. Although we could not precisely link transcript level changes and neurologic pathogenesis, this study provides a more comprehensive understanding of the PKU-affected brain at the molecular level, possibly resulting in better therapeutic approaches.

Original languageEnglish
JournalMolecular Genetics and Metabolism
Volume86
Issue numberSUPPL.
DOIs
Publication statusPublished - 2005 Dec 1

Fingerprint

Gene therapy
Dependovirus
Phenylketonurias
Viruses
Transcriptome
Gene expression
Genetic Therapy
Genes
Phenylalanine Hydroxylase
Brain
Phenylalanine
Hypopigmentation
Immunoglobulin Heavy Chains
Nociceptors
Protein Precursors
Osteocalcin
Sensory Receptor Cells
Muramidase
Oligonucleotide Array Sequence Analysis
Transgenes

Keywords

  • Adeno-associated virus
  • Gene therapy
  • Microarray
  • Mouse
  • Neurological pathogenesis
  • Phenylketonuria

ASJC Scopus subject areas

  • Biochemistry
  • Genetics
  • Endocrinology, Diabetes and Metabolism

Cite this

Reversal of gene expression profile in the phenylketonuria mouse model after adeno-associated virus vector-mediated gene therapy. / Oh, Hyun Jeong; Lee, Hyejin; Park, Joo Won; Rhee, Hwanseok; Koo, Soo Kyung; Kang, Seong Man; Jo, Inho; Jung, Sung Chul.

In: Molecular Genetics and Metabolism, Vol. 86, No. SUPPL., 01.12.2005.

Research output: Contribution to journalArticle

Oh, Hyun Jeong ; Lee, Hyejin ; Park, Joo Won ; Rhee, Hwanseok ; Koo, Soo Kyung ; Kang, Seong Man ; Jo, Inho ; Jung, Sung Chul. / Reversal of gene expression profile in the phenylketonuria mouse model after adeno-associated virus vector-mediated gene therapy. In: Molecular Genetics and Metabolism. 2005 ; Vol. 86, No. SUPPL.
@article{637c03afa77647e8be422fb94621a96d,
title = "Reversal of gene expression profile in the phenylketonuria mouse model after adeno-associated virus vector-mediated gene therapy",
abstract = "Phenylketonuria (PKU) is an autosomal recessive metabolic disorder caused by phenylalanine hydroxylase (PAH) deficiency. Accumulation of phenylalanine leads to severe mental and psychomotor retardation, and hypopigmentation of skin and hair. We have demonstrated the cognitive outcome of biochemical and phenotypic reversal by the adeno-associated virus vector-mediated gene delivery of a human PAH transgene. In this study, we identified the expression of genes related to pathologic abnormalities of the PKU-affected brain, in which the symptoms of PKU are mainly manifest, and transcriptional changes in effective gene therapy treatment using oligonucleotide array. Therapeutic effectiveness was verified by change in enzyme activity (15 ± 5.84{\%}), phenylalanine plasma level (261 ± 108 μM), and coat color. Our data indicated that 12 genes were significantly up-regulated in PKU. Four are involved in defense and inflammatory responses of neutrophils (NE, MPO, NGP, and CRAMP), three other overexpressed genes are related to extracellular matrix organization and degradation (COL1A1, COL1A2, and MMP13); the remainder were a nociceptor in sensory neurons (MrgA1), a structural gene of P lysozyme (Lzp-s), an immunoglobulin α heavy chain constant region gene (Igh-2), an osteocalcin-related protein precursor (Bglap-rs1), and a membrane-spanning 4 domain, subfamily A, member 3 (Ms4a3). Data demonstrated that elevated genes in the PKU-affected brain could be normalized by human PAH gene delivery. Although we could not precisely link transcript level changes and neurologic pathogenesis, this study provides a more comprehensive understanding of the PKU-affected brain at the molecular level, possibly resulting in better therapeutic approaches.",
keywords = "Adeno-associated virus, Gene therapy, Microarray, Mouse, Neurological pathogenesis, Phenylketonuria",
author = "Oh, {Hyun Jeong} and Hyejin Lee and Park, {Joo Won} and Hwanseok Rhee and Koo, {Soo Kyung} and Kang, {Seong Man} and Inho Jo and Jung, {Sung Chul}",
year = "2005",
month = "12",
day = "1",
doi = "10.1016/j.ymgme.2005.06.015",
language = "English",
volume = "86",
journal = "Molecular Genetics and Metabolism",
issn = "1096-7192",
publisher = "Academic Press Inc.",
number = "SUPPL.",

}

TY - JOUR

T1 - Reversal of gene expression profile in the phenylketonuria mouse model after adeno-associated virus vector-mediated gene therapy

AU - Oh, Hyun Jeong

AU - Lee, Hyejin

AU - Park, Joo Won

AU - Rhee, Hwanseok

AU - Koo, Soo Kyung

AU - Kang, Seong Man

AU - Jo, Inho

AU - Jung, Sung Chul

PY - 2005/12/1

Y1 - 2005/12/1

N2 - Phenylketonuria (PKU) is an autosomal recessive metabolic disorder caused by phenylalanine hydroxylase (PAH) deficiency. Accumulation of phenylalanine leads to severe mental and psychomotor retardation, and hypopigmentation of skin and hair. We have demonstrated the cognitive outcome of biochemical and phenotypic reversal by the adeno-associated virus vector-mediated gene delivery of a human PAH transgene. In this study, we identified the expression of genes related to pathologic abnormalities of the PKU-affected brain, in which the symptoms of PKU are mainly manifest, and transcriptional changes in effective gene therapy treatment using oligonucleotide array. Therapeutic effectiveness was verified by change in enzyme activity (15 ± 5.84%), phenylalanine plasma level (261 ± 108 μM), and coat color. Our data indicated that 12 genes were significantly up-regulated in PKU. Four are involved in defense and inflammatory responses of neutrophils (NE, MPO, NGP, and CRAMP), three other overexpressed genes are related to extracellular matrix organization and degradation (COL1A1, COL1A2, and MMP13); the remainder were a nociceptor in sensory neurons (MrgA1), a structural gene of P lysozyme (Lzp-s), an immunoglobulin α heavy chain constant region gene (Igh-2), an osteocalcin-related protein precursor (Bglap-rs1), and a membrane-spanning 4 domain, subfamily A, member 3 (Ms4a3). Data demonstrated that elevated genes in the PKU-affected brain could be normalized by human PAH gene delivery. Although we could not precisely link transcript level changes and neurologic pathogenesis, this study provides a more comprehensive understanding of the PKU-affected brain at the molecular level, possibly resulting in better therapeutic approaches.

AB - Phenylketonuria (PKU) is an autosomal recessive metabolic disorder caused by phenylalanine hydroxylase (PAH) deficiency. Accumulation of phenylalanine leads to severe mental and psychomotor retardation, and hypopigmentation of skin and hair. We have demonstrated the cognitive outcome of biochemical and phenotypic reversal by the adeno-associated virus vector-mediated gene delivery of a human PAH transgene. In this study, we identified the expression of genes related to pathologic abnormalities of the PKU-affected brain, in which the symptoms of PKU are mainly manifest, and transcriptional changes in effective gene therapy treatment using oligonucleotide array. Therapeutic effectiveness was verified by change in enzyme activity (15 ± 5.84%), phenylalanine plasma level (261 ± 108 μM), and coat color. Our data indicated that 12 genes were significantly up-regulated in PKU. Four are involved in defense and inflammatory responses of neutrophils (NE, MPO, NGP, and CRAMP), three other overexpressed genes are related to extracellular matrix organization and degradation (COL1A1, COL1A2, and MMP13); the remainder were a nociceptor in sensory neurons (MrgA1), a structural gene of P lysozyme (Lzp-s), an immunoglobulin α heavy chain constant region gene (Igh-2), an osteocalcin-related protein precursor (Bglap-rs1), and a membrane-spanning 4 domain, subfamily A, member 3 (Ms4a3). Data demonstrated that elevated genes in the PKU-affected brain could be normalized by human PAH gene delivery. Although we could not precisely link transcript level changes and neurologic pathogenesis, this study provides a more comprehensive understanding of the PKU-affected brain at the molecular level, possibly resulting in better therapeutic approaches.

KW - Adeno-associated virus

KW - Gene therapy

KW - Microarray

KW - Mouse

KW - Neurological pathogenesis

KW - Phenylketonuria

UR - http://www.scopus.com/inward/record.url?scp=28844474908&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=28844474908&partnerID=8YFLogxK

U2 - 10.1016/j.ymgme.2005.06.015

DO - 10.1016/j.ymgme.2005.06.015

M3 - Article

VL - 86

JO - Molecular Genetics and Metabolism

JF - Molecular Genetics and Metabolism

SN - 1096-7192

IS - SUPPL.

ER -